BC Extra | Aug 29, 2019
Financial News

MedImmune-spinout Viela seeking $150M IPO

Autoimmune disease company Viela proposed Thursday to raise up to $150 million in an IPO -- two days after FDA accepted its first BLA for review, and two months after it closed a $75 million...
BC Innovations | Nov 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: October 2018

New Therapeutic Targets and Biomarkers: October 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October. Therapeutic targets are defined as any protein, gene or other molecule...
BC Innovations | Oct 3, 2018
Distillery Therapeutics

Neurology

INDICATION: Frontotemporal dementia Patient sample and fruit fly studies suggest inhibiting ATP5F1B could help treat FUS proteinopathy, a group of neurodegenerative diseases that includes frontotemporal lobe dementia. In postmortem brain samples from patients with FUS-associated...
BC Innovations | Jun 7, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: May 2018

New Therapeutic Targets and Biomarkers: May 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during May 2018. Therapeutic targets are defined as any protein, gene or other...
BC Innovations | May 23, 2018
Distillery Therapeutics

Neurology; musculoskeletal

INDICATION: Amyotrophic lateral sclerosis (ALS); musculoskeletal In vitro , cell culture and fruit fly studies suggest promoting the expression of TNPO1 could help treat ALS caused by FUS mutations and multisystem proteinopathy caused by HNRNPA1 mutations....
BC Innovations | Mar 12, 2015
Targets & Mechanisms

TBK1 and beyond

Biogen Idec Inc. 's partnership with Columbia University and the HudsonAlpha Institute for Biotechnology has yielded a new target in ALS - TBK1 - that provides a link between autophagy, neuroinflammation and the pathology of the disease....
BC Innovations | Dec 19, 2013
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Amyotrophic lateral sclerosis (ALS) Fusion (involved in t(12;16) in malignant liposarcoma) (FUS; TLS) Cell culture studies suggest oligonucleotides that induce FUS exon seven skipping could...
BC Innovations | Aug 29, 2013
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Amyotrophic lateral sclerosis (ALS) Fusion (involved in t(12;16) in malignant liposarcoma) (FUS; TLS) Mouse studies suggest inhibiting FUS aggregation could help...
BC Week In Review | Nov 21, 2011
Company News

Invida, Menarini deal

Menarini acquired Asia-Pacific commercialization services firm Invida. Invida, which has annual revenue of more than $220 million, markets products in the consumer health, dermatology and primary and specialty care spaces across 13 markets in the...
BC Extra | Nov 16, 2011
Company News

Menarini invades Asia-Pacific with Invida buy

Menarini Group (Florence, Italy) acquired Asia-Pacific commercialization services firm Invida Group Pte. Ltd. (Singapore). Invida, which has annual revenue of more than $220 million, markets products in the consumer health, dermatology and primary and specialty...
Items per page:
1 - 10 of 14